NCT00055822已完成1 期
A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2002年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Oblimersen may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drugs.
PURPOSE: Phase I/II trial to study the effectiveness of combining oxaliplatin, fluorouracil, and leucovorin with oblimersen in treating patients who have unresectable, metastatic, or recurrent colorectal cancer.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose of oblimersen when administered with oxaliplatin, fluorouracil, and leucovorin calcium in patients with advanced colorectal cancer.
- Determine the quantitative and qualitative toxic effects of this regimen in these patients.
- Determine the antitumor activity of this regimen in these patients.
- Determine the plasma pharmacokinetics of oblimersen and oxaliplatin in patients treated with this regimen.
- Determine relevant predictive biomarkers of response in patients treated with this regimen.
OUTLINE: This is an open-label, phase I, dose-escalation study of oblimersen followed by a non-randomized, phase II study.
- Phase I: Patients receive oblimersen IV continuously on days 1-5 and 15-19; leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 6, 7, 20, and 21; and oxaliplatin IV over 2 hours on days 6 and 20.
Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed adenocarcinoma of the colon or rectum
- •Unresectable, metastatic, or recurrent disease
- •Measurable or evaluable disease (phase I)
- •Measurable disease (phase II)
- •No known brain metastases
- •Patients with previously treated brain metastases who are not currently receiving steroids and have a stable CT scan or MRI are eligible
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •ECOG 0-2 OR
- •Karnofsky 60-100%
- •Life expectancy
- •At least 12 weeks
- •Hematopoietic
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Hemoglobin at least 9 g/dL
- •Bilirubin no greater than 1.5 mg/dL
- •AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
- •INR no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy)
- •PT/PTT no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy)
- •Creatinine normal OR
- •Creatinine clearance at least 60 mL/min
- •Cardiovascular
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No cardiac arrhythmia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No history of allergic reaction to compounds of similar chemical or biologic composition to fluorouracil or oxaliplatin
- •No other concurrent uncontrolled medical condition that would preclude study participation
- •No ongoing or active infection
- •No psychiatric illness or social situation that would preclude study compliance
- •No known history of degenerative facet disease during prior fluorouracil therapy
- •No HIV-positive patients receiving combination antiretroviral therapy
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •No concurrent epoetin alfa during course 1
- •No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)
- •No concurrent immunotherapy
- •Chemotherapy
- •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- •No prior oxaliplatin
- •No other concurrent chemotherapy
- •Endocrine therapy
- •See Disease Characteristics
- •Radiotherapy
- •At least 4 weeks since prior radiotherapy and recovered
- 另有 5 项未显示
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Mixed Cell LymphomaStage IV Adult Diffuse Small Cleaved Cell LymphomaStage IV Adult Hodgkin LymphomaStage IV Adult Immunoblastic Large Cell LymphomaStage IV Adult Lymphoblastic LymphomaStage IV Adult T-cell Leukemia/LymphomaStage IV Cutaneous T-cell Non-Hodgkin LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaStage IV Marginal Zone LymphomaStage IV Small Lymphocytic LymphomaUnspecified Adult Solid Tumor, Protocol SpecificNCT00060112National Cancer Institute (NCI)15
终止
1 期
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerAdenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric CancerSquamous Cell Carcinoma of the EsophagusStage III Esophageal CancerStage IIIA Gastric CancerStage IIIB Gastric CancerStage IIIC Gastric CancerStage IV Esophageal CancerStage IV Gastric CancerNCT00064259National Cancer Institute (NCI)15
Unknown
2 期
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyLung CancerNCT00022243Tularik
已完成
1 期
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung CancerLung CancerNCT00005032University of Chicago12
已完成
1 期
Chemotherapy in Treating Patients With Breast CancerBreast CancerNCT00012129NYU Langone Health